Get the latest information on 400+ supplements and their effects on 500+ health outcomes.
By becoming an Examine Plus member, you'll have access to all of the latest nutrition research. Quickly and easy look up evidence on over 400 supplements across over 500 different health goals, outcomes, conditions, and more.
Research Breakdown on Phosphatidylserine
Phosphatidylserine (PS) is a naturally occurring phospholipid that exists in all species, and comprises a portion of the phospholipid pool in human brain (15%), lungs (7.4%), testes (6.4%), kidneys (5.7%), liver (3.8%), skeletal muscle (3.3%), heart (3.2%) and blood plasma (0.2%) with an estimated 60g total PS storage in the body where half exists in neural tissue. The average dietary intake is said to be approximately 130mg daily.
Phosphatidylserine (PS) is found in:
Neural tissue (with past studies sourcing supplemental PS from bovine cortex, has since fallen out of favor due to risk of bovine spongiform encephalopathy)
Phosphatidylserine (PS) is a structure somewhat similar to a triacylglyceride (storage form of dietary fat), but with two fatty acids (diacylglyceride) with the final bonding site on glycerol occupied by a phosphatadic acid molecule and serine amino acid. Various compounds may be called phosphatidylserine given they have that one serine containing group; the other two fatty acid chains are irrelevant to the naming, but not necessarily the function, and may differ depending on source.
Phosphatidylserine is a triglyceride structure with one fatty acid replaced with a phosphatic acid and a serine amino acid, and is a phospholipid structure due to this
Phosphatidylserine concentrations in the brain appear to decline with age when measuring rat cerebral slices with no significant alterations in red blood cells in humans (despite some alterations present in rats during the aging process).
After synthesis, PS is then used as a structural component of a cell's lipid bilayer (cell membrane) with the serine molecule facing inwards. When included in the structure of the cell membrane, it seems to contribute to and increase cell fluidity and have positive influences on the enzymes Na+/K+ stimulated ATPase (upregulation) and acetylcholinesterase (downregulation) which may lead to its effects on cognition. There was an upper limit of enzymatic activation noted at 1umol/mg membrane protein, but this cannot be easily translated into an upper dosage.
The first source of supplemental phosphatidylserine was that from the bovine cortex, and while on a molecular level and for some practises there are no significant differences between bovine cortex and soy lecithin based phosphatidylserine the reduction in cortisol seen with bovine cortex PS injections and oral supplementation does not appear to occur with soy lecithin based PS when orally supplemented.
Relative to the commonly supplemented soy lecithin based phosphatidylserine, the PS derived from bovine brain tissue is structurally the same yet implicated in reducing cortisol (maybe due to other compounds in the extract), but the bovine brain derived PS is no longer used due to concerns over Creutzfeldt–Jakob disease
Phosphatidylserine has recently started to be extracted from sunflower oil, and at this moment in time there do not appear to be much research into its effects in living organisms nor a known reason to supplement over soy lecithin based phosphatidylserine.
There is currently a lack of information on phosphatidylserine sourced from sunflower oil Other studies in children with ADHD have noted promise when pairing PS with fish oil supplementation, with some using a phosphatidylserine structure with the fish oil fatty acids (EPA and DHA) attached to the glycerol backbone(study duplicated in Medline) and appears to enhance erythrocytic fish oil fatty acid levels to a level greater than fish oil itself (a phenomena seen with krill oil; fish oil fatty acids bound as phosphatidylcholine). In otherwise healthy young adults given 400mg PS for 2 weeks, a significant improvement in processing speed (20%) and accuracy (13% more correct responses, 39% less wrong responses) is noted relative to placebo and independent of mood state.
Phosphatidylserine appears to promote attention and reduce symptoms of ADHD, and when the phosphatidylserine molecule contains the fish oil fatty acids then it may promote attention to an even greater degreefish oil (and stress was only significantly reduced at rest in high stressed persons); it has been replicated elsewhere with phosphatidylserine in isolation with 42 days supplementation of 200mg phosphatidylserine (as protein bar) where induced stresses were less than control (and associated with less beta-1 wave function in the right hemisphere). This same dose and supplementation vessel has been used in young golfers given 200mg phosphatidylserine for 42 days, where a 21.6% increase in drive accuracy (percentage of straight shots) was thought to be secondary to a stress reducing effect. Using cortisol as a biomarker, stress levels during cognitive testing appear to be unaffected despite improvement in performance and some studies in healthy individuals fail to find any salient effect. Regardless, studies that measure heart rate changes during stress fail to find a significant influence of supplementation.
Phosphatidylserine supplementation appears to exert anti-stress effects in otherwise healthy persons without stress disorders following prolonged supplementation, and this appears to possibly be independent of the classical biomarkers of stress reduction (cortisol, heart rate)
The anti-stress effect appears to be somewhat different than other supplements and not 100% reliable, and it is uncertain how phosphatidylserine is doing this. It does, however, appear to extend to both soy lecithin based and bovine cortex based phosphatidylserine which does not appear extend to young rats. It has been noted that administration of 200mg (intravenous injection) of phospholipids to patients with Alzheimer's is able to increase dopamine and serotonin metabolites, which are normally reduced in cognitive decline. Phosphatidylserine has been found to preserve glucose metabolism during Alzheimer's disease by 13.5–16% following ingestion of 500mg phosphatidylserine which may be a mechanism underlying its observed benefit in some instances. In studies assessing cognitive decline in Alzheimer's via the MMSE, there appears to be a collection of studies suggesting no effect with 500mg for 3 weeks but benefit with 300mg of phosphatidylserine from bovine cortex for 8 weeks or 12 weeks and has been noted to have benefit with 400mg over 6 months to a level greater than pyritinol. One study using the MMSE as a rating scale in elderly persons with age-related cognitive decline (but not diagnosed Alzheimer's) has also noted an improvement with 300mg bovine cortex phosphatidylserine. In other cognitive disease states, persons with Parkinson's disease given bovine cerebral phosphatidylserine note some degree of improvement on EEG parameters and in general dementia 300mg of bovine cortex phosphatidylserine has noted some degree of benefit within 3 weeks of a 6 week trial and has improved memory and depressive symptoms in persons suffering from geriatric depression.
In persons with age-related cognitive decline associated with pathology, there appears to be a large body of evidence to support the role of bovine cortex phosphatidylserine in alleviating symptoms at 300mg daily. However, there is a lack of evidence to support the role of soy lecithin-based phosphatidylserine in this role and some suspicion that it may not be as effective and has been noted at lower concentrations (5-20mg/kg) when injected into aged rats, where improvements in grooming and behaviour retention are noted. Studies in non-aged rats (to establish a nootropic effect rather than cognitive rehabilitative effect) using 50mg/kg bodyweight for 27 days was able to significantly enhance brightness discrimination (indicative of memory formation) without significantly affecting anxiety or depressive symptoms.
There appears to be a memory promoting effect of phosphatidylserine supplementation in rats that occurs in cognitively damaged models, aged rat models, and young rats as well; the dosage used in these rat studies is higher than usual (around 500mg for a non-obese human) but not unfeasibly highThe first report of cognitive improvment in elderly humans with aging associated mental impairment (non-pathological) was 3 months of 300mg soy-based phosphatidylserine (PS), in which scores on the Wechsler Memory test improved with particular improvement in visual memory; this was later replicated with 300mg PS over 12 weeks and two studies have noted that PS supplementation appears to aid in face recognition in elderly persons at this dose. Other studies note that 100 or 300mg daily for 6 months has failed to outperform placebo on the Rivermead behavioral memory test (test catered for 'everyday memory problems') while scores on the Hasegawa dementia scale (HDS-R; used for dementia assessment similar to the MMSE) improved relative to placebo, and MMSE score improved as well. Improvements in the former parameter has been noted elsewhere in elderly persons with memory complaints when using a phosphatidylserine molecule complexed with DHA or phosphatidylserine from bovine cortex at 100mg but soy based phosphatidylserine up to 600mg daily (6 months) has been noted to fail with similar methodology. In studies that assess more quantifiable parameters, supplementation of PS (where fish oil fatty acids were added to the structure) reported an improvement in immediate word recall by 42% in elderly subjects.
In healthy elderly adults, there appears to be benefit associated with long term supplementation of phosphatidylserine which seems to be more catered towards preventing dementia; benefits to practical cognition, such as working memory and cognition in everyday situations (or at least rating scales thought to be indicative of this), seems somewhat mixed and may be restricted to PS complexed with fish oils Elsewhere, supplementation of this dose of soy based PS has failed to alter the exercise-induced changes in lipid peroxidation, muscle soreness, or inflammation. which was later replicated with 10 days supplementation of 800mg bovine cortex phosphatidylserine in otherwise healthy men subject to exercise. Studies using soy lecithin-derived phosphatidylserine noted that 400mg PS delivered via a protein bar format (some nutrient confounds) for 2 weeks in college-aged men does not appear to significant alter exercise-induced changes in cortisol nor ACTH and 750mg of PS daily for 10 days has twice failed to significantly influence cortisol/ACTH in otherwise healthy exercising men. This apparent discrepancy appears to be either due to other molecules that may coexist with bovine cortex but not soy lecithin (eg. sphingomyelin) or the fatty acids bound to the glycerol backbone in the relative sources.
Phosphatidylserine derived from the bovine cortex appears to reduce cortisol in high concentrations, there is no evidence to support the role of soy based phosphatidylserine in this role and evidence to actively disprove an ability of PS to suppress cortisol or ACTHFish oil (the fatty acids EPA and DHA) are components of phosphatidylserine (PS) derived from bovine cerebral cortex but not from soy lecithin, and some authors mention that combination therapy of both fatty acids with PS would lead to better results. Both phospholipids and polyunsaturated fatty acids are constituents of lipid membranes, and are thought by some to work synergistically. 300mg phosphatidylserine paired with 37.5mg of fish oil fatty acids has been noted to improve delayed word recall in older individuals by 42% relative to baseline (no placebo control) with immediate recall not affected nor was any other tested parameter (attention, reaction time, working memory, etc.); this effect size may be larger than it actually is due to the low sample size (n=8). In adult men (non-elderly) using capsules containing fish oil (25% DHA, 5% EPA) and phosphatidylserine (20-22%) at 300mg daily (total PS 60-66mg) noted reduced stress levels in subjects who reported higher baseline chronic stress levels; those with lower stress failed to see an effect to chronic stress, but both groups experienced a lessening of percieved stress during testing (to a lower magnitude in the low stress group).fish oil fatty acids (EPA and DHA) results in a complexed form that has been used in a few studies with benefit.Ginkgo biloba is a cognitive enhancing herb, with at least one study noted that despite inefficacy with 120mg of ginkgo that complexing this herb with phosphatidylserine results in enhanced memory, with a degree greater than that seen with ginkgo complexed with phosphatidylcholine (which also outperformend ginkgo in isolation).
Further testing is required, but the two agents may be synergisticsoy lecithin due to a higher safety profile.
- Hellhammer J, et al. Omega-3 fatty acids administered in phosphatidylserine improved certain aspects of high chronic stress in men. Nutr Res. (2012)
- Richter Y, et al. The effect of phosphatidylserine-containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints: a pilot study. Clin Interv Aging. (2010)
- Manor I, et al. Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: A double-blind placebo-controlled trial followed by an open-label extension. Eur Psychiatry. (2013)
- Argentiero V, Tavolato B. Dopamine (DA) and serotonin metabolic levels in the cerebrospinal fluid (CSF) in Alzheimer's presenile dementia under basic conditions and after stimulation with cerebral cortex phospholipids (BC-PL). J Neurol. (1980)
- Monteleone P, et al. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology. (1990)
- Phospholipids and sports performance.
- Brain Cephalin, a mixture of Phosphatides. Separation from it of Phosphatidyl serine, Phosphatidyl ethanolamine, and a fraction containing an inositol Phosphatide.
- Miranda DT, et al. Soy lecithin supplementation alters macrophage phagocytosis and lymphocyte response to concanavalin A: a study in alloxan-induced diabetic rats. Cell Biochem Funct. (2008)
- Prusiner SB. Molecular biology of prion diseases. Science. (1991)
- Calderini G, et al. Biochemical changes of rat brain membranes with aging. Neurochem Res. (1983)
- Schroeder F. Role of membrane lipid asymmetry in aging. Neurobiol Aging. (1984)
- Franco RS, et al. Changes in the properties of normal human red blood cells during in vivo aging. Am J Hematol. (2013)
- How Old Are Dense Red Blood Cells? The Dog's Tale.
- Christian JA, et al. Senescence of canine biotinylated erythrocytes: increased autologous immunoglobulin binding occurs on erythrocytes aged in vivo for 104 to 110 days. Blood. (1993)
- Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med. (1995)
- Tsakiris S, Deliconstantinos G. Influence of phosphatidylserine on (Na+ + K+)-stimulated ATPase and acetylcholinesterase activities of dog brain synaptosomal plasma membranes. Biochem J. (1984)
- Kaibuchi K, Takai Y, Nishizuka Y. Cooperative roles of various membrane phospholipids in the activation of calcium-activated, phospholipid-dependent protein kinase. J Biol Chem. (1981)
- Specht SC, Robinson JD. Stimulation of the (Na + + K + )-dependent adenosine triphosphatase by amino acids and phosphatidylserine: chelation of trace metal inhibitors. Arch Biochem Biophys. (1973)
- Sakai M, Yamatoya H, Kudo S. Pharmacological effects of phosphatidylserine enzymatically synthesized from soybean lecithin on brain functions in rodents. J Nutr Sci Vitaminol (Tokyo). (1996)
- Suzuki S, et al. Oral administration of soybean lecithin transphosphatidylated phosphatidylserine improves memory impairment in aged rats. J Nutr. (2001)
- Monteleone P, et al. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol. (1992)
- Parker AG, et al. The effects of IQPLUS Focus on cognitive function, mood and endocrine response before and following acute exercise. J Int Soc Sports Nutr. (2011)
- Hirayama S, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet. (2013)
- Manor I, et al. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry. (2012)
- Vaisman N, et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr. (2008)
- Schuchardt JP, et al. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis. (2011)
- Winther B, et al. Elucidation of phosphatidylcholine composition in krill oil extracted from Euphausia superba. Lipids. (2011)
- Baumeister J, et al. Influence of phosphatidylserine on cognitive performance and cortical activity after induced stress. Nutr Neurosci. (2008)
- The effect of phosphatidylserine on golf performance.
- Rosadini G, et al. Phosphatidylserine: quantitative EEG effects in healthy volunteers. Neuropsychobiology. (1990-1991)
- Phosphatidylserine increases acetylcholine release from cortical slices in aged rats.
- Effect of Phosphatidylserine on Acetylcholine Output from the Cerebral Cortex of the Rat.
- Casamenti F, Scali C, Pepeu G. Phosphatidylserine reverses the age-dependent decrease in cortical acetylcholine release: a microdialysis study. Eur J Pharmacol. (1991)
- Calderini G, et al. Pharmacological effect of phosphatidylserine on age-dependent memory dysfunction. Ann N Y Acad Sci. (1985)
- Effect of Phosphatidylserine on Cerebral Glucose Metabolism in Alzheimer's Disease.
- Amaducci L. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull. (1988)
- Engel RR, et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol. (1992)
- Crook T, et al. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull. (1992)
- Heiss WD, et al. Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation. Dementia. (1994)
- Cenacchi T, et al. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano). (1993)
- Fünfgeld EW, et al. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT). Prog Clin Biol Res. (1989)
- Delwaide PJ, et al. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand. (1986)
- Maggioni M, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand. (1990)
- Zanotti A, Valzelli L, Toffano G. Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats. Psychopharmacology (Berl). (1989)
- Drago F, Canonico PL, Scapagnini U. Behavioral effects of phosphatidylserine in aged rats. Neurobiol Aging. (1981)
- Kataoka-Kato A, et al. Enhanced learning of normal adult rodents by repeated oral administration of soybean transphosphatidylated phosphatidylserine. J Pharmacol Sci. (2005)
- The effect of plant phosphatidylserine of age—associated memory impairment and mood in the functioning elderly.
- Effects of phosphatidylserine in age‐associated memory impairment.
- Schreiber S, et al. An open trial of plant-source derived phosphatydilserine for treatment of age-related cognitive decline. Isr J Psychiatry Relat Sci. (2000)
- Wilson B, et al. The development and validation of a test battery for detecting and monitoring everyday memory problems. J Clin Exp Neuropsychol. (1989)
- Hosokawa T, et al. Psychometric equivalence of the Hasegawa Dementia Scale-Revised with the Mini-Mental State Examination in stroke patients. Percept Mot Skills. (1994)
- Kato-Kataoka A, et al. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. J Clin Biochem Nutr. (2010)
- Vakhapova V, et al. Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial. Dement Geriatr Cogn Disord. (2010)
- Crook TH, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology. (1991)
- Jorissen BL, et al. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. Nutr Neurosci. (2001)
- Kingsley MI, et al. Effects of phosphatidylserine on exercise capacity during cycling in active males. Med Sci Sports Exerc. (2006)
- Kingsley MI, et al. Phosphatidylserine supplementation and recovery following downhill running. Med Sci Sports Exerc. (2006)
- Ottestad I, et al. Fish oil supplementation alters the plasma lipidomic profile and increases long-chain PUFAs of phospholipids and triglycerides in healthy subjects. PLoS One. (2012)
- Kennedy DO, et al. Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine. Hum Psychopharmacol. (2007)
- Jorissen BL, et al. Safety of soy-derived phosphatidylserine in elderly people. Nutr Neurosci. (2002)